{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Will be estimated using the Kaplan-Meier product-limit method.","groups":[{"description":"Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.\n\nPembrolizumab: Given 200 mg/kg IV.\n\nRadiation Therapy: Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.","id":"OG000","title":"Radiation Therapy, Pembrolizumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From first treatment on course 1, day 1 to the earlier of date of death and/or last follow up, assessed up to 12 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"participants"}